Jia Liu/LinkedIn
Jul 20, 2025, 16:48
Jia (Jenny) Liu: Sharing Industry Insights from Recent Achievements on Quantitative Biomarkers
Jia (Jenny) Liu, Translational Lead of The Kinghorn Cancer Centre, shared a post on LinkedIn:
“Hadassah Sade sharing industry insights from recent achievements on quantitative biomarkers including the AstraZeneca TROP2 quantitative continuous scoring using AI and deep learning as biomarker for DatoDXD in NSCLC.
Multiplexing is key especially to facilitate tumor agnostic indications and to address the equity issue for patients with rare cancers.”
More posts featuring AstraZeneca on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Aug 12, 2025, 16:02
Aug 12, 2025, 15:59
Aug 12, 2025, 15:50
Aug 12, 2025, 15:43
Aug 12, 2025, 15:37
Aug 12, 2025, 15:30
Aug 12, 2025, 15:29